enGene Therapeutics Inc. is a clinical-stage biotechnology company focused on mainstreaming gene therapy through non-viral delivery of therapeutics to mucosal tissues and other organs. Its lead program, detalimogene voraplasmid (detalimogene), targets non-muscle invasive bladder cancer (NMIBC), particularly in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS), with or without papillary disease. This therapy is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, including a pivotal cohort. enGene Therapeutics Inc. leverages its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables localized delivery of diverse gene cargos such as DNA and various forms of RNA directly to target tissues. Operating in the biotechnology and medical research sector, the company addresses diseases with high unmet clinical needs by developing genetic medicines that penetrate mucosal barriers effectively. Headquartered in Saint-Laurent, Quebec, Canada, enGene Therapeutics Inc. plays a role in advancing innovative treatments for oncology and other challenging indications through its DDX technology.